Heinz Ludwig, MD, discusses the incidence of increased infections in patients with multiple myeloma.
Heinz Ludwig, MD, professor of internal medicine and hematology-oncology at Wilhelminen Cancer Research Institute, Wilhelminenspital in Vienna, Austria, discusses the incidence of increased infections in patients with multiple myeloma.
Patients with multiple myeloma are at increased risk to develop infections due to its significant impact on one's immune system. In a study, Ludwig et al discovered that about 56% of patients had 1 or more infectious episodes prior to their diagnosis due to the innate immune system.
According to Ludwig, a majority of the viral infections which occur in patients with multiple myeloma are in the upper respiratory tract and primarily consist of viral infections. However, infections of the bloodstream, urinary tract infections and those caused by bacteria are also common.
Transcription:
0:08 | We did a study, which showed that myeloma patients, about 56% of patients, had already 1 or more infectious episodes in the year before the diagnosis was established. Patients are at increased risk and the increased risk is already affecting about half of patients before any treatment has been initiated. The disease itself is immunosuppressive, it has a significant impact on what we call the innate immune system.
0:54 | Then when patients are treated, they are the complications of inside effects of therapy. Usually when they are treated, there's more disease which motivates people to start therapy. In addition, there is a gender difference. Male myeloma patients are at a 20% higher risk of infections compared to females. As you know, male patients have slightly poorer survival expectancy compared to female patients.
Supportive Care Helps Manage AEs With Teclistamab in R/R Multiple Myeloma
December 13th 2024During a Case-Based Roundtable® event, Hana Safah, MD, discussed updated data and adverse event management related to teclistamab in patients with multiple myeloma in the second article of a 2-part series.
Read More
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More
ctDNA Detection Tied to Tumor Burden, Recurrence in HR+ Early Breast Cancer
December 13th 2024A phase 2 trial showed ctDNA detection in HR-positive early breast cancer was linked to larger tumors, higher residual cancer burden, and increased recurrence after neoadjuvant endocrine therapy.
Read More
Supportive Care Helps Manage AEs With Teclistamab in R/R Multiple Myeloma
December 13th 2024During a Case-Based Roundtable® event, Hana Safah, MD, discussed updated data and adverse event management related to teclistamab in patients with multiple myeloma in the second article of a 2-part series.
Read More
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More
ctDNA Detection Tied to Tumor Burden, Recurrence in HR+ Early Breast Cancer
December 13th 2024A phase 2 trial showed ctDNA detection in HR-positive early breast cancer was linked to larger tumors, higher residual cancer burden, and increased recurrence after neoadjuvant endocrine therapy.
Read More
2 Commerce Drive
Cranbury, NJ 08512